Nyxoah to Release First Half 2021 Financial Results on August 31 and Host Earnings Conference Call on September 1, 2021
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nyxoah SA (Nasdaq: NYXH) announced its plan to release financial results for the first half of 2021 on August 31, 2021, after US markets close. A conference call will be held on September 1, 2021, at 3:00 p.m. CET to discuss these results. The company focuses on innovative solutions for treating Obstructive Sleep Apnea (OSA) and has made progress with its Genio® system, which received European CE Mark approval in 2019. Nyxoah is currently conducting pivotal studies for FDA approval and further research on the therapy's long-term efficacy.
Positive
- Successful completion of BLAST OSA study supporting Genio® system.
- Genio® system received European CE Mark in 2019.
- Ongoing DREAM IDE pivotal study aiming for FDA approval.
Negative
- None.
Details
News Market Reaction – NYXH
The recorded move for NYXH in the trading session of this news was -0.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mont-Saint-Guibert, Belgium. - August 11, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it will release financial results for the first half of 2021 on Tuesday, August 31, 2021, after the US markets close. Company management will host a conference call to discuss financial results on Wednesday, September 1, 2021, beginning at 3:00 p.m. CET / 9:00 a.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 260-3718 for US, 0800 73264 for Belgium, or (929) 517-0938 for international callers, followed by Conference ID: 7468474. A live and archived webcast of the event will be available on the Company’s investors relations website at https://investors.nyxoah.com/.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company has completed the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion and is currently conducting the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.
For more information, please visit http://www.nyxoah.com/.
Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
corporate@nyxoah.com
+32 (0)10 22 24 55
Gilmartin Group
Vivian Cervantes
IR@nyxoah.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.